| CAS ID: | 36791-04-5 |
| Molecular Formula: | C8H12N4O5 |
| Molecular Weight: | 244.2 g/mol |
| Monoisotopic Mass: | 244.0808 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | COPEGUS | Viramid | Ribofluranosyl Carboxamide | RIBASPHERE | VIRAZOLE | REBETOL | RIBAVIRIN | TRIBAVIRIN | RibaPak | RIBAVARIN | VIRAZID |
| Analysis: | Drug repositioning mechanism analysis |
Reference Record 1
| PubMed ID | 21901059 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Liver fibrosis |
| Process I | |||
| Process II | |||
| Process III | |||
| Mechanism | |||
Trial Record 1
| ClinicalTrial ID | NCT00148837 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Unknown |
| First Received | September 8, 2005 | Last Verified | February 8, 2008 |
| Sponsor | French National Agency for Research on AIDS and Viral Hepatitis | ||
Trial Record 2
| ClinicalTrial ID | NCT00323804 | Disease | Liver fibrosis |
| Phase | Phase 2,Phase 3 | Status | Completed |
| First Received | May 10, 2006 | Last Verified | September 4, 2014 |
| Sponsor | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | ||
Trial Record 3
| ClinicalTrial ID | NCT00840489 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Terminated |
| First Received | February 10, 2009 | Last Verified | January 31, 2013 |
| Sponsor | Hospital Universitario Ramon y Cajal | ||
Trial Record 4
| ClinicalTrial ID | NCT02319031 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | December 18, 2014 | Last Verified | January 27, 2017 |
| Sponsor | Bristol-Myers Squibb | ||
Trial Record 5
| ClinicalTrial ID | NCT01634919 | Disease | Liver fibrosis |
| Phase | Status | Unknown | |
| First Received | July 6, 2012 | Last Verified | October 11, 2017 |
| Sponsor | Seoul National University Boramae Hospital | ||
Trial Record 6
| ClinicalTrial ID | NCT00006164 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 9, 2000 | Last Verified | May 11, 2018 |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | ||
Trial Record 7
| ClinicalTrial ID | NCT01508286 | Disease | Liver fibrosis |
| Phase | Status | - | |
| First Received | January 11, 2012 | Last Verified | July 24, 2015 |
| Sponsor | Janssen-Cilag International NV | ||
Trial Record 8
| ClinicalTrial ID | NCT00709059 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | July 3, 2008 | Last Verified | November 4, 2015 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 9
| ClinicalTrial ID | NCT00039871 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | June 14, 2002 | Last Verified | April 4, 2017 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 10
| ClinicalTrial ID | NCT02464631 | Disease | Liver fibrosis |
| Phase | Not Applicable | Status | Terminated |
| First Received | June 8, 2015 | Last Verified | January 19, 2017 |
| Sponsor | Institute of Liver and Biliary Sciences, India | ||
Trial Record 11
| ClinicalTrial ID | NCT01463956 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | November 2, 2011 | Last Verified | January 24, 2017 |
| Sponsor | French National Agency for Research on AIDS and Viral Hepatitis | ||
Trial Record 12
| ClinicalTrial ID | NCT00301509 | Disease | Liver fibrosis |
| Phase | Phase 2,Phase 3 | Status | Completed |
| First Received | March 13, 2006 | Last Verified | March 13, 2006 |
| Sponsor | Casa Sollievo della Sofferenza IRCCS | ||
Trial Record 13
| ClinicalTrial ID | NCT00383864 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Completed |
| First Received | October 4, 2006 | Last Verified | October 6, 2006 |
| Sponsor | Hospital Clinic of Barcelona | ||
Trial Record 14
| ClinicalTrial ID | NCT00687219 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | May 30, 2008 | Last Verified | April 7, 2017 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 15
| ClinicalTrial ID | NCT02705534 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | March 10, 2016 | Last Verified | April 30, 2018 |
| Sponsor | Tehran University of Medical Sciences | ||
Trial Record 16
| ClinicalTrial ID | NCT02596880 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | November 4, 2015 | Last Verified | October 18, 2016 |
| Sponsor | Tehran University of Medical Sciences | ||
Trial Record 17
| ClinicalTrial ID | NCT01006031 | Disease | Liver fibrosis |
| Phase | Phase 2,Phase 3 | Status | Completed |
| First Received | November 2, 2009 | Last Verified | December 30, 2011 |
| Sponsor | Sociedad Andaluza de Enfermedades Infecciosas | ||
Trial Record 18
| ClinicalTrial ID | NCT01687257 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | September 18, 2012 | Last Verified | September 16, 2016 |
| Sponsor | Gilead Sciences | ||
Trial Record 19
| ClinicalTrial ID | NCT00304551 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | March 20, 2006 | Last Verified | June 3, 2010 |
| Sponsor | Chugai Pharmaceutical | ||
Trial Record 20
| ClinicalTrial ID | NCT00811967 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Terminated |
| First Received | December 19, 2008 | Last Verified | March 13, 2017 |
| Sponsor | Merck Sharp & Dohme Corp. | ||
Trial Record 21
| ClinicalTrial ID | NCT02996682 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | December 19, 2016 | Last Verified | February 26, 2019 |
| Sponsor | Gilead Sciences | ||
Trial Record 22
| ClinicalTrial ID | NCT02265237 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | October 15, 2014 | Last Verified | August 31, 2017 |
| Sponsor | AbbVie | ||
Trial Record 23
| ClinicalTrial ID | NCT02219477 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 19, 2014 | Last Verified | July 11, 2017 |
| Sponsor | AbbVie | ||
Trial Record 24
| ClinicalTrial ID | NCT02207088 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 1, 2014 | Last Verified | November 9, 2017 |
| Sponsor | AbbVie | ||
Trial Record 25
| ClinicalTrial ID | NCT02201901 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | July 28, 2014 | Last Verified | November 15, 2018 |
| Sponsor | Gilead Sciences | ||
Trial Record 26
| ClinicalTrial ID | NCT01995071 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | November 26, 2013 | Last Verified | October 16, 2017 |
| Sponsor | AbbVie | ||
Trial Record 27
| ClinicalTrial ID | NCT01888900 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | June 28, 2013 | Last Verified | February 7, 2017 |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | ||
Trial Record 28
| ClinicalTrial ID | NCT02517528 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 7, 2015 | Last Verified | October 8, 2018 |
| Sponsor | AbbVie | ||
Trial Record 29
| ClinicalTrial ID | NCT01704755 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | October 11, 2012 | Last Verified | October 19, 2015 |
| Sponsor | AbbVie (prior sponsor, Abbott) | ||
Trial Record 30
| ClinicalTrial ID | NCT01939197 | Disease | Liver fibrosis |
| Phase | Phase 2,Phase 3 | Status | Completed |
| First Received | September 11, 2013 | Last Verified | November 17, 2017 |
| Sponsor | AbbVie | ||
Trial Record 31
| ClinicalTrial ID | NCT00489385 | Disease | Liver fibrosis |
| Phase | Phase 1 | Status | Completed |
| First Received | June 21, 2007 | Last Verified | July 2, 2017 |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) | ||
| PubChem: | 37542 |
| ChEMBL: | CHEMBL1643 |